Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2008-04-15
2008-04-15
Marschel, Ardin H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S002600, C514S004300, C424S001130, C424S452000
Reexamination Certificate
active
07358222
ABSTRACT:
Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.
REFERENCES:
patent: 4393053 (1983-07-01), Gonella et al.
patent: 4904786 (1990-02-01), Musser et al.
patent: 5116616 (1992-05-01), Gonenne
patent: 5610288 (1997-03-01), Rubenstein et al.
patent: 5667766 (1997-09-01), Wilson et al.
patent: 5760041 (1998-06-01), Wissner et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5894018 (1999-04-01), Davila et al.
patent: 5932481 (1999-08-01), Pon et al.
patent: 5968748 (1999-10-01), Bennett et al.
patent: 6288082 (2001-09-01), Wissner et al.
patent: 6551989 (2003-04-01), Nadel et al.
patent: 6602863 (2003-08-01), Bridges et al.
patent: 6627634 (2003-09-01), Himmelsbach et al.
patent: 760766 (2000-03-01), None
patent: 1792207 (1971-11-01), None
patent: 4117078 (1992-11-01), None
patent: 0 635 498 (1995-01-01), None
patent: WO 90/03374 (1990-04-01), None
patent: WO 92/18481 (1992-10-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 97 19065 (1997-05-01), None
patent: WO 99 32121 (1999-07-01), None
patent: WO 00/10588 (2000-03-01), None
Guzman, et al. “Epidermal growth factor regulates expression of the mucous phenotype of rat tracheal epithelial cells”,Biochem. Biophys. Res. Com., (1995) vol. 217(2):412-418.
Branch (1998) “A good antisense molecule is hard to find.”Trends in Biochem. Sci., vol. 23:45-50.
Crooke (1998)Antisense Research and Application, published by Springer-Verlag, Chapter 1:1-50.
Crystal (1995) “Transfer of genes to humans: early lessons and obstacles to success.”Science, vol. 270(5235):404-10.
Donato et al (1989), “Tumor Necrosis Factor Modulates Epidermal Growth Factor Receptor Phosphorylation and Kinase Activity in Human Tumor Cells,”The Journal of Biological Chemistry, vol. 264(34): 20474-20481.
Desseyn et al. (1997), “Human Mucin Gene MUC5B, the 10.7-kb Large Central Exon Encodes Various Alternate Subdomains Resulting in a Super-repeat,”The Journal of Biological Chemistry, vol. 272(6): 3168-3178.
Friedmann (1997) “Overcoming the obstacles to gene therapy.”Sci Am., vol. 276(6):96-101.
Goldstein et al. (1995), “Biological Efficacy of a Chimeric Antibody to the Epidermal Growth Factor Receptor in a Human Tumor Xenograft Model,”Clinical Cancer Research, vol. 1: 1311-1318.
Grandis, Jr., et al. (1997) “Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.”Oncogene, vol. 15(4):pp. 409-416.
Kawamoto et al. (1983), Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors fo epidermal growth factor by an anti-receptor monoclonal antibody,Proc. Natl. Acad. Sci. USA, vol. 80: 1337-1341.
Kondapaka et al. (1996), “Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer,”Molecular and Cellular Endocrinology, vol. 117: 53-58.
Kumar et al. (1998) “Cooperative interaction of autocrine and paracrine mitogens for airway epithelial cells.”Cell Biology and Toxicology, vol. 14(4):pp. 293-299.
Levitski (1994), “Signal-transduction therapy, a novel approach to disease management”,Eur. J. Biochem., vol. 226(1):1-13.
Lorimer, et al. (1995), “Immunotoxins that Target an Oncogenic Mutant Epidermal Growth Factor Receptor Expressed in Human Tumors”,Clinical Cancer Research, vol. 1: 859-864.
Petit er al. (1997), “Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2
euReceptor Tyrosine Kinases Down-Regulated Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo,”American Journal of Pathology, vol. 151(6): 1523-1530.
Powis (1994), “Signaling pathways as targets for anticancer drug development”,Pharmac. Ther., vol. 62:57-95.
Schmidt et al. (1996), “Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα,”British Journal of Cancer, vol. 74: 853-862.
Schofield et al. (1995) “Non-viral approaches to gene therapy.”British Medical Bulletin, vol. 51(1):56-71.
Takeyama et al. (1998), Neutrophil-dependent goblet cell degranulation: role of membrane-bound elastase and adhesion molecules,Am. J. Physiol., vol. 275:294-302.
Takeyama et al. (1999) “Epidermal growth factor system regulates mucin production in airways.”Proceedings of the National Academy of Sciences USA, vol. 96(6):pp. 3081-3086.
Takeyama et al. (2000) “Oxidative Stress Causes Mucin Synthesis via Transactivation of Epidermal Growth Factor Receptor: Role of Neutrophils.”Journal of Immunology, vol. 164(3):1546-1552.
Temann et al. (1997), A Novel Role of Murine IL-4 In Vivo: Induction of MUC5AC Gene Expression and Mucin Hypersecretion,Am J. Respir. Cell Biol., vol. 16:471-478.
Ullrich et al. (1984), “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.”
Verma et al. (1997) “Gene therapy—promises, problems and prospects.”Nature, vol. 389(6648):239-42.
Zhang et al. (1996) “Sensitization of HER-2
eu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.”Oncogene, vol. 12(3):571-6.
Van Herwaarden et al., “The role of N-acetylcysteine in the treatment of chronic obstructive pulmonary disease.” Netherlands Journal of Medicine, 47 (1995): 45-48.
Amishma, M. et al., Expression of epidermal growth factor and epidermal growth factor receptor immunoraeactivity in the asthmatic human airway.: American Journal of Respiratory and Critical Care medicine, vol. 157, No. 6, Jun. 1998,n pp. 1907-1912.
Kim et al., (2000), “Levels in Intracellular Protein and Messenger RNA of Mucin and Lysozyme in Normal Human Nasal and Polyp Epithelium” The Laryngoscope, vol. 110, No. 2, pt. 1, pp. 276-280.
Burgel et al., (2000), “Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps” Journal of Allergy and Clinical Immunology, vol. 106, No. 4, pp. 705-712.
Nadel, (2001) “Role of epidermal growth factor receptor activation in regulating mucin synthesis” Respiratory Research, vol. 2, No. 2, pp. 85-89.
Nadel et al., (2001)“The role of epidermal growth factor in mucus production” Current Opinion in Pharmacology, vol. 1, No. 3, pp. 254-258.
Lee et al., (2001), “Epidermal growth factor receptor signaling mediates regranulation of rat nasal goblet cells” Journal of Allergy and Clinical Immunology, vol. 107, No. 6, pp. 1046-1050.
Nadel Jay A.
Takeyama Kiyoshi
Borden Paula A.
Bozicevic Field & Francis LLP
Gembeh Shirley V
Marschel Ardin H.
Sherwood Pamela J.
LandOfFree
Preventing airway mucus production by administration of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventing airway mucus production by administration of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventing airway mucus production by administration of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2774336